Sunday, June 10, 2012

Rosacea News May 2012

1. Why Has No One Found a Cure for Rosacea?

Why has no one found something even remotely close to a cure for rosacea ? Why do researchers admit that they can barely even describe the disease ? Well a clue emerges from a recent series of in depth, state of the art papers from the Journal of Investigative Dermatology Symposium Proceedings. In the introductory item title  “Pathophysiology of Rosacea: Introduction”, Dr. Martin Steinhoff …

2. Scenesse Starts Phase III Trials for EPP in the US

News today that Scenesse has progressed another step towards wider approval with the commencement of Phase III Trials. About 100 people with the condition Erythropoietic Protoporphyria (EPP) will be double blinded to receive the Scenesse implant or placebo. …

3. Smokers Much Less Likely to get Rosacea

Yes you read correctly, some recent research conducted in the UK has found that smoking is associated with a substantially reduced risk of developing rosacea. The study …

4. How Much Would You Pay to Cure Your Rosacea?

Most published abstracts are a pretty dry read. This one is about as dry as they come. How about titling it “Rosacea Sufferers Willing To Pay Less than Vitiligo, …

5. Coblation with Saline and Radio Frequency Induced Plasma: Rhinophyma Miracle

The Daily Mail continues to show itself as the premier newspaper for rosacea related news stories. This last weekend the paper has a great …

6. Rosaliac AR Intense from La Roche-Posay

In 2010 La Roche Posay  took the opportunity of the rosacea awareness month and their support of the National Rosacea Society to promote their product – Rosaliac UV Fortifying Anti-Redness Moisturizer with SPF 15.

7. Novartis Buys Fougera for $1.5B, gets Generic Metrogel

News today that the giant pharmaceutical company Novartis International is buying Fougera Pharmaceuticals.

Fougera is known to rosacea sufferers through the availability of generic metronidazole 0.75%. Fougera will brings its specialty in generics to Sandoz, the generics division of Novartis.